Oxford-based SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly and currently incurable disease, has been awarded a £2 million BioMedical …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
